IP Library Granted Patent US 9,688,716
Granted Patent B2
US 9,688,716 · App. 14/383,405 · Granted Jun 27, 2017

Crystalline forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor

Inventors: Suizhen Lin (Guangzhou, CN); Jingxia Zhang (Guangzhou, CN); Xinhua Li (Guangzhou, CN)
Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.
C07J1/0007C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,688,716
App. No.
14/383,405
Granted
Jun 27, 2017
Kind
B2
Abstract

The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5α-androstane-3β,5,6β-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2θ values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

Claims (16)

1. A method for preparing a crystalline form of 5α-androstane-3β,5,6β-triol,

comprising:

dissolving 5α-androstane-3β,5,6β-triol in a solvent to form a mixture, with a ratio of the 5α-androstane-3β,5,6β-triol to the solvent being 1g:10˜120 mL;

heating the mixture to 50˜80° C.;

adding another solvent to dilute the mixture;

cooling the mixture; and

allowing the mixture to form a crystalline precipitate,

wherein the crystalline form is a transparent needle-shaped crystal, and belongs to monoclinic crystal system and space group P2 1 , and

wherein the crystalline form is characterized by lattice parameters of a=11.3±0.2 Å, b=7.4±0.2 Å, c=20.5±0.2 Å, α=90.0°, β=95.0±0.5°, γ=90.0°; and characterized by diffraction peaks at diffraction angle 2θ values of 4.3±0.2, 8.6±0.2, 12.9±0.2, 17.2±0.2, 21.6±0.2 degrees; and characterized by an endothermic transition temperature of 223±2° C.

2. The method of claim 1 , wherein the solvent for dissolving is acetone, ethyl acetate or ethanol, and

the solvent for diluting is the same as the solvent for dissolving or a poor solvent selected from water, hexamethylene and petroleum ether.

3. The method of claim 2 , wherein

when acetone or ethanol is used as the solvent for dissolving and water is used as the poor solvent for diluting, the mixture is diluted at a ratio of 1:2.5-5;

when acetone or ethanol is used as the solvent for dissolving and hexamethylene or petroleum ether is used as the poor solvent for diluting, the mixture is diluted at a ratio of 1:1-5;

when ethyl acetate is used as the solvent for dissolving and ethyl acetate is used as the solvent for diluting, the mixture is diluted at a ratio of 1:1-5; and

when ethyl acetate is used as the solvent for dissolving and hexamethylene or petroleum ether is used as the poor solvent for diluting, the mixture is diluted at a ratio of 1:1-5.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 033711 FRAME: 0569. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 16, 2017
From: LIN, SUIZHEN; ZHANG, JINGXIA; LI, XINHUA
To: GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD.
Reel/Frame 042480/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2014
From: LIN, SUIZHEN; ZHANG, JINGXIA; LI, XINHUA
To: GUANGZHOU CELPROTEK PHARMACEUTICAL CO., LTD.
Reel/Frame 033711/0569 →
Priority Claims (1)
CN 2012 1 0060611 · Mar 8, 2012 · national
Continuity (1)
Related Publication 20150045566A1 · Feb 12, 2015